Expression and significance of lncRNA SNHG25 in prostate cancer based on the TCGA database
10.3969/j.issn.1009-8291.2024.03.006
- VernacularTitle:基于TCGA数据库分析lncRNA SNHG25在前列腺癌中的表达及其意义
- Author:
Hai KANG
1
;
Xiaoying LIU
2
;
Jie ZHAO
2
;
Song ZHOU
1
;
Xiangyong JIANG
1
;
Tieqiu LI
1
Author Information
1. Department of Urology, The First Affiliated Hospital of Hunan Normal University/Hunan Provincial People’s Hospital, Changsha 410002, China
2. Department of Pathology, The First Affiliated Hospital of Hunan Normal University/Hunan Provincial People’s Hospital, Changsha 410002, China
- Publication Type:Journal Article
- Keywords:
lncRNA SNHG25;
prostate cancer;
TCGA database;
ceRNA;
enrichment analysis
- From:
Journal of Modern Urology
2024;29(3):224-231
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To analyze the expression of lncRNA SNHG25 in prostate cancer and its significance, so as to explore the biomarkers and potential therapeutic targets for the diagnosis and prognosis of this disease. 【Methods】 Based on the TCGA database, differential, survival, and clinical correlation analyses of SNHG25 were performed.SNHG25 expression in prostate cancer was analyzed in the UALCAN database to determine its relationship with the clinical and pathological characteristics.The lncRNA-miRNA-mRNA correlation analysis was performed.The relevant ceRNA regulatory network was constructed.Prostate cancer samples were divided into high and low SNHG25 expression groups, and differential SNHG25 related genes were filtered and then enriched. 【Results】 SNHG25 expression was significantly upregulated in prostate cancer specimens compared to normal prostate specimens (P<0.001), and the progression-free survival of the low SNHG25 expression group was significantly longer than that of the high SNHG25 expression group (P<0.001).There were no significant differences in age, T-stage and N-stage between the two groups, and there was no significant correlation between the expression of SNHG25 and Gleason score (P>0.05).Regulatory networks of SNHG25/miR-330-3p/DLX1 and RPL22L1 were constructed. 【Conclusion】 SNHG25 is highly expressed in prostate cancer tissues and correlated with poor prognosis.SNHG25 expression does not significantly correlate with age, T-stage, N-stage, and Gleason score.SNHG25/miR-330-3p/DLX1 and RPL22L1 regulatory networks may play an important role in the development of prostate cancer.SNHG25 may become a biomarker and potential therapeutic target for prostate cancer.
